Treatment Information

Back

Colon Cancer treatment details. Chemotherapy, Biologic therapy.

UCLA, Santa Monica, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Santa Monica, CA
Treatments:Chemotherapy, Biologic therapyHospital:UCLA
Drugs:Journal:Link
Date:Jun 2015

Description:

Patients:
This phase 2 study involved metastatic colorectal cancer patients who were divided into two separate treatment groups. Group A had 96 patients with a median age of 61 years; 64% were male. Group B had 95 patients with a median age of 60 years; 65% were male.

Treatment:
Patients in group A received chemotherapy with the mFOLFOX6 regimen (oxaliplatin, leucovorin, 5-fluorouracil) and biologic therapy with sunitinib (a tyrosine kinase inhibitor).

Patients in group B received chemotherapy with the mFOLFOX6 regimen (oxaliplatin, leucovorin, 5-fluorouracil) and biologic therapy with bevacizumab.

Toxicities:
Adverse event-related deaths due to cardiac and respiratory problems and progressive disease were reported for group A. Grade 3-4 neutropenia, fatigue, and thrombocytopenia were also reported.

Adverse event-related deaths due to progressive disease were reported for group B. Grade 3-4 neutropenia, fatigue, and diarrhea were also reported.

Results:
The median overall survival times for groups A and B were 23.7 and 34.1 months, respectively.

Support:
This study was supported by Pfizer Inc.

Correspondence: Dr. J Randolph Hecht; email: jrhecht@mednet.ucla.edu



Back